Onselex Pharmaceuticals is a biotechnology company developing a next-generation nanomedicine platform designed to improve the therapeutic index of established oncology drugs.

Our lead program,ONX-1006, is a nanoparticle drug candidate that encapsulates paclitaxel within a stable structure. It is designed to enhance tumor accumulation, support sustained drug exposure, and reduce off-target exposure to healthy cells.

Across extensive GLP toxicology and preclinical studies, ONX-1006 has demonstrated a favorable safety profile, including established No Observed Adverse Effect Level, or NOAEL, findings. In validated xenograft models, ONX-1006 also demonstrated statistically significant tumor suppression and superior anti-tumor activity compared with Abraxane.

We are currently focused on metastatic pancreatic cancer, one of the most aggressive and underserved cancers. Despite available treatments such as FOLFIRINOX and Abraxane, survival outcomes remain limited, and significant unmet need persists.

Our current mission is to advance ONX-1006 into clinical evaluation and expand our nanoparticle platform across multiple solid tumors and future therapeutic areas.

At Onselex, we are committed to disciplined science, rigorous development, and responsible execution. We sincerely appreciate our partners and long-term shareholders who share our vision.

If you would like to learn more about Onselex or explore becoming a shareholder, please contact us by email.

Thank you very much for your consideration.

Ernie Shin